PeSaCUP: Pessary Satisfaction Criteria for Urogenital Prolapse

Sponsor
University Hospital, Caen (Other)
Overall Status
Recruiting
CT.gov ID
NCT03615872
Collaborator
(none)
150
1
59.4
2.5

Study Details

Study Description

Brief Summary

Genital prolapse is a common pathology with a prevalence ranging from 2.9 to 11.4% or 31.8% to 97.7%, depending on whether a questionnaire or clinical examination is used. The use of pessary in the treatment of prolapse remains discussed despite a satisfaction rate of 50 to 80% in the literature and a minimal complications rate.

The main objective of this study is to assess the satisfaction of patients carrying a pessary in the first year after the laying.

Condition or Disease Intervention/Treatment Phase
  • Device: pessary use

Detailed Description

This is a prospective observational cohort conducted at the Universitary hospital of Caen over a total period of 5 years.

Patients with a symptomatic genital prolapse will all be offered the installation of a pessary. If they agree to participate in the study, they will be asked to respond to validated questionnaires: symptom questionnaires (PFDI-20, ICIQ-SF, USP), a sexuality questionnaire (PISQ-12), a quality of life questionnaire (PFIQ-7, BIS) and Satisfaction (PGI-I), several times: Before the installation of the pessary, at one month, at 6 months, then annually over 5 years

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
150 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Evaluation of Patient Satisfaction With Pessary in the Treatment of Genital Prolapse
Actual Study Start Date :
Jun 20, 2018
Actual Primary Completion Date :
Jun 20, 2018
Anticipated Study Completion Date :
Jun 1, 2023

Outcome Measures

Primary Outcome Measures

  1. Patient SATISFACTION assessed by the PGI-I score (Patient Global Impression of Improvement) in the first year after the installation of a pessary [1 year]

    The PGI-I score was developed and validated to quantify the effect of urinary incontinence or prolapse treatments

Secondary Outcome Measures

  1. Patient SATISFACTION assessed by the PGI-I score (Patient Global Impression of Improvement) every year for five years after the installation of a pessary [1 to 5 years]

    The PGI-I score was developed and validated to quantify the effect of urinary incontinence or prolapse treatments

  2. EFFICACY of pessary on genital symptoms assessed by the Pelvic Floor Distress Inventory (PFDI-20) questionnaire before and after the installation of the pessary. [at 1 year, then every year for 5 years]

    This score was developped to evaluate the genital, anorectal and urinary symptoms related to genital prolapse

  3. EFFICACY of pessary on urinary symptoms assessed by the International Consultation of Incontinence Questionnaire-Short Form (ICIQ-UI SF) and the Urinary Symptom Profile score (USP) before and after the installation of the pessary. [at 1 year, then every year for 5 years]

    These scores are self-questionnaires specifically validated to evaluate urinary incontinence and urinary tract dysfunctions

  4. Sexual impact of pessary assessed by the Pelvic organ prolapse urinary Incontinence Sexual Questionnaire (PISQ-12) [at 1 year, then every year for 5 years]

    Evaluation of the PISQ-12 score after the installation of a pessary. This score was developped specifically to evaluate sexual troubles in case of genital prolapse

  5. QUALITY OF LIFE assessed by the Pelvic Floor Impact Questionnaire (PFIQ-7) before and after the installation of the pessary [at 1 year, then every year for 5 years]

    The PFIQ-7 was developped to evaluate the impact of the symptoms on the quality of life

  6. INVESTIGATE the impact of age on the removal or expulsion of pessary [1 year to 5 years]

    Impact of age (years) on treatment failure (removal or expulsion of pessary)

  7. INVESTIGATE the impact of menopausal status on the removal or expulsion of pessary [1 year to 5 years]

    Impact of menopausal status (yes/no) on treatment failure (removal or expulsion of pessary)

  8. INVESTIGATE the impact of weight on the removal or expulsion of pessary [1 year to 5 years]

    Impact of weight (Kg) on treatment failure (removal or expulsion of pessary)

  9. INVESTIGATE the impact of hysterectomy history on the removal or expulsion of pessary [1 year to 5 years]

    Impact of hysterectomy history (yes/no) on the removal or expulsion of pessary

  10. INVESTIGATE the impact of prolapse surgery history on the removal or expulsion of pessary [1 year to 5 years]

    Impact of prolapse surgery history (yes/no) on the removal or expulsion of pessary

  11. INVESTIGATE the impact of the prolapse stage of on the removal or expulsion of pessary [1 year to 5 years]

    Impact of the prolapse stage (assessed by the validated POP-Q classification) of on the removal or expulsion of pessary. The stage of prolapse is ranged from 1 to 4 in the POP-Q classification

  12. Complications of pessary use reported by their rate [1 to 5 years]

    Rate of complications related to the use of a pessary (frequencies)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • The research protocol will be proposed to all patients with a symptomatic genital prolapse, over 18 years of age, who speak French and who agree to participate in this study

  • Prolapse defined according to the International Classification POP-Q-.

Exclusion Criteria:
  • Minors under 18 years of age

  • Pregnant or lactating women

  • Women Not speaking French (the good understanding of French is necessary to answer questionnaires and for informed information)

  • Women unable to understand due to cognitive impairment or degenerative disease (dementia/ Alzheimer's disease)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Pizzoferato Caen France 14000

Sponsors and Collaborators

  • University Hospital, Caen

Investigators

  • Principal Investigator: Anne Cecile PIZZOFERRATO, MD, Universitary Hospital of Caen

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University Hospital, Caen
ClinicalTrials.gov Identifier:
NCT03615872
Other Study ID Numbers:
  • 2018-A00004-51
First Posted:
Aug 6, 2018
Last Update Posted:
Aug 31, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Caen
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 31, 2021